AI pharmaceutical company Iambic Therapeutics has applied for a stock market listing on Nasdaq under the ticker IAM. Details of the listing have not been disclosed.
The capital will primarily be used to develop three cancer drug candidates. Iambic was founded in 2019 and has so far raised around 462 million dollars from investors including Nvidia, Qatar Investment Authority and Coatue Management.
The company uses AI and automated chemistry and biology for drug development and collaborates, among others, with Abbvie, Takeda, Lundbeck, Bayer and Jazz Pharmaceuticals.
